Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Syrrx’s Structural Proteomics At Heart Of Pharmacia Alliance

Jan. 25, 2002

By Aaron Lorenzo

Triangle Plans NDA For One Drug, Discontinues Another

Jan. 22, 2002

By Aaron Lorenzo

Triangle Plans NDA For One Drug, Discontinues Another

Jan. 22, 2002

By Aaron Lorenzo

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Jan. 16, 2002

By Aaron Lorenzo

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Jan. 16, 2002

By Aaron Lorenzo

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Jan. 15, 2002

By Aaron Lorenzo

Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Jan. 15, 2002

By Aaron Lorenzo

Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

Enzon, Inhale Enter Broad Deal On Pegylation, Licensing, Lawsuit

Jan. 9, 2002

By Aaron Lorenzo

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.